SPOTLIGHT -
Dr. Alva on the Shift Toward Combination Therapy in mRCC
Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Read More
Dr. Alva on Results of the CABOSUN Trial in RCC
Ajjai Shivaram Alva, MBBS, discusses the results of the CABOSUN trial in renal cell carcinoma.
Dr. Alva on TKI Monotherapy and Combinations for RCC
Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.
Dr. Alva on the Toxicity Profiles of TKIs in RCC
Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
